


## **Pandorum Technologies and Nucleon Therapeutics focus on treating ocular diseases in APAC region**

06 January 2026 | News

**Reaffirming India's growing capability to develop and manufacture cutting-edge biologic therapies for the world**



Pandorum Technologies, a clinical-stage regenerative medicine company building a next-generation platform for programmable tissue regeneration, has announced a strategic collaboration with Nucleon Therapeutics, a specialised contract research, development and manufacturing organisation (CRDMO), to expand manufacturing capabilities for Pandorum's exosome-based therapeutic platform across the Asia-Pacific (APAC) region.

This strategic collaboration aligns with a shared vision, as Pandorum's asset(s) progress toward clinical trials. By leveraging Nucleon Therapeutics' manufacturing capabilities, the partnership supports regional supply and regulatory readiness, marking a strategic step forward. Furthermore, it reaffirms India's growing capability to develop and manufacture cutting-edge biologic therapies for the world.

While the current programmes span ocular surface injury and inflammatory corneal diseases, including Stevens–Johnson syndrome (SJS), Neurotrophic Keratitis, Pandorum plans to expand its disease modifying treatments to reverse degenerative changes of skin, pulmonary, and other organ systems, affected by inflammation, vascular pathologies and fibrosis.

Nucleon Therapeutics is a wholly owned subsidiary of India-based Bharat Biotech, a leading vaccine and biotechnology companies. It will provide end-to-end manufacturing support, including process scale-up, GMP-compliant production, and quality control of pharmaceutical-grade exosomes derived from clinical-grade mesenchymal stem cells.

Pandorum is pioneering a tunable exosome platform designed to reprogramme diseased tissues by precisely modulating intercellular communication pathways. The company's approach is grounded in the principle that tissues are learnable, dynamic biological systems, and that controlled delivery of biologically encoded signals—via designer extracellular vesicles

(exosome) can restore tissue structure and function in conditions driven by inflammation, fibrosis, and loss of regenerative capacity.